- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01155817
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
PRIMARY OBJECTIVES:
Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD.
SECONDARY OBJECTIVES:
Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z1M9
- Gordon and Leslie Diamond Health Care Centre Hematology Administration
-
-
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University School of Medicine
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Colorado Blood Cancer Institute
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:5.1.1 Steroid dependent/refractory cGVHD defined as:
- Dependent disease - Persistent cGVHD manifestations requiring a glucocorticoid dose >= prednisone 0.25 mg/kg/day (0.5 mg/kg po qod) for at least 12 weeks.
- Refractory disease - Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednisone 0.5 mg/kg/day (1 mg/kg po qod) for at least 4 weeks.
5.1.2 Any previous treatments for cGVHD (except nilotinib). Participants may have received nilotinib for other reasons besides cGVHD such as leukemia or solid tumor.
5.1.3 Participants must be receiving baseline systemic glucocorticoid therapy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting nilotinib.
5.1.4 At the time of trial enrollment, participants may be receiving one or two other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting nilotinib. Monoclonal T or B cell antibodies must be discontinued at least 28 days before starting nilotinib.
5.1.5 Chronic GVHD manifestations that can be followed on physical or laboratory exam. A list of potential manifestations is presented in Appendix D.
- Skin changes
- Oral mucosa changes
- Hepatic dysfunction
5.1.6 >= 18 years old
5.1.7 Life expectancy >= 6 months.
5.1.8 Karnofsky performance status >= 60 (defined as being unable to work, able to live at home, and able to care for most personal needs but requiring occasional assistance from others).
5.1.9 Laboratory parameters:
- Creatinine < 1.5 x ULN
- ANC > 1.5 x 10^9/L
- Platelets > 100 x 10^9/L
- Total bilirubin < 1.5 x ULN
- AST (SGOT) and ALT (SGPT) < 2.5 x ULN
- Serum amylase and lipase <= 1.5 x ULN
- Alkaline phosphatase <= 2.5 x ULN
- Patients must have the following laboratory values within normal limits at the local institution lab or corrected to within normal limits with supplements prior to the first dose of study medication:
Potassium Magnesium Phosphorus Calcium
5.1.10 Oxygen saturation during exertion maintained at >= 88% on room air.
5.1.11 Ability to understand and willingness to sign a written informed consent form.
5.1.12 Females with reproductive potential must have a negative pregnancy test <= 7 days before starting nilotinib. Reproductive potential will be defined as having at least 1 menstrual period in the past 12 months. Male and female subjects with reproductive potential agree to the use of barrier contraception during their treatment and for up to 3 months after the last dose.
5.1.13 Careful rationalization of concomitant medications with the intent to discontinue or change to alternative medications when any concomitant medications are identified that have the potential to prolong the QTcB interval or are associated with an increased risk of torsades de pointes. (Appendix B)
5.1.14 . Careful rationalization of concomitant medications with the intent to discontinue or change to alternative medications if any concomitant medications are identified to be strong CYP3A4 inhibitors. (Appendix C)
5.1.15 Myeloablative or non-myeloablative allogeneic hematopoietic cell transplant.
Exclusion Criteria:5.2.1 Currently receiving or has received within 28 days of starting study drug nilotinib or any other tyrosine kinase inhibitor.
5.2.2 Received any anti-T or anti-B cell monoclonal antibody <= 28 days prior to the anticipated start of study drug.
5.2.3 Currently receiving > two immunosuppressants other than glucocorticoids.
5.2.4 Currently receiving a calcineurin inhibitor and sirolimus
5.2.5 Received any investigational agents <= 28 days before starting nilotinib.
5.2.6 Impaired cardiac function including any one of the following:
- Clinically significant resting brachycardia (<50 beats per minute).
- QTc > 450 msec on baseline ECG. If QTc >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
- Myocardial infarction within 12 months prior to starting study.
- Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension).
- History of or presence of clinically significant ventricular or atrial tachyarrhythmias. (including congenital long QT syndrome or a known family history of congenital long QT syndrome)
5.2.7 Allogeneic cell infusion within 100 days
5.2.8 Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines.
5.2.9 Progressive malignant disease including post transplant lymphoproliferative disease.
5.2.10 Any secondary malignancy except basal and squamous cell carcinoma of the skin within the past five years.
5.2.11 Nilotinib intolerance or hypersensitivity. 5.2.12 Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery).
5.2.13 Acute or chronic pancreatic disease 5.2.14 Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered from prior surgery.
5.2.15 Subject is pregnant, breast-feeding, or of childbearing potential without a negative serum or urine pregnancy test within 7 days of enrollment. Male or female patients of childbearing potential unwilling to use effective contraceptive precautions throughout the trial.
5.2.16 Subject not willing to comply with treatment or response evaluation (including associated procedures such as skin biopsy).
5.2.17 Subject has a concurrent illness which in the opinion of the investigator may interfere with the treatment and evaluation of the patient.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Nilotinib
|
200, 400, 800, oral
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Frequency and severity of adverse events graded according to CTCAE v4.0
Periodo de tiempo: 2 years
|
2 years
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Chronic GVHD response measured as change in physical exam and laboratory testing
Periodo de tiempo: baseline and 2 years
|
baseline and 2 years
|
Chronic GVHD response measured as change in daily corticosteroid requirement
Periodo de tiempo: baseline and 2 years
|
baseline and 2 years
|
Chronic GVHD response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cGVHD
Periodo de tiempo: 2 years
|
2 years
|
Chronic GVHD response measured as change in cGVHD symptom burden
Periodo de tiempo: baseline and 2 years
|
baseline and 2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: George Chen, Stanford University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB-18743 (Otro identificador: Stanford IRB)
- SU-06112010-6317 (Otro identificador: Stanford University)
- BMT222 (Otro identificador: OnCore)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Linfoma No Hodgkin
-
Rutgers, The State University of New JerseyTerminadoMBSR-STEM | PMR-STEM | MBSR-NON-STEM | PMR - SIN VÁSTAGOEstados Unidos
-
National Cancer Institute (NCI)TerminadoLinfoma de Hodgkin en adultos recidivante | Linfoma de Hodgkin en adultos en estadio III | Linfoma de Hodgkin en adultos en estadio IV | Linfoma de Hodgkin infantil recidivante/refractario | Linfoma de Hodgkin infantil en estadio III | Linfoma de Hodgkin infantil en estadio IV | Linfoma de Hodgkin... y otras condicionesEstados Unidos
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminadoLinfoma de Hodgkin recurrente | Linfoma de Hodgkin refractario | Linfoma no Hodgkin de células B refractario | Linfoma no Hodgkin de células T refractario | Linfoma no Hodgkin de células B recurrente | Linfoma no Hodgkin de células T recurrenteEstados Unidos
-
University of WashingtonReclutamientoLinfoma de Hodgkin recurrente | Linfoma de Hodgkin refractario | Linfoma no Hodgkin recurrente | Linfoma no Hodgkin refractarioEstados Unidos
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityTerminadoLinfoma de Hodgkin en adultos | Linfoma no Hodgkin en adultosFederación Rusa
-
Marker Therapeutics, Inc.ReclutamientoNo linfoma de Hodgkin | Linfoma no Hodgkin en adultos | Linfoma no Hodgkin, refractario | Linfoma no Hodgkin en recaídaEstados Unidos
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Activo, no reclutandoLinfoma de Hodgkin en estadio III de Ann Arbor | Linfoma de Hodgkin en estadio IIIA de Ann Arbor | Linfoma de Hodgkin en estadio IIIB de Ann Arbor | Linfoma de Hodgkin en estadio IV de Ann Arbor | Linfoma de Hodgkin en estadio IVA de Ann Arbor | Linfoma de Hodgkin en estadio IVB de Ann Arbor | Linfoma... y otras condicionesEstados Unidos
-
Tessa TherapeuticsActivo, no reclutandoLinfoma de Hodgkin en adultos | Enfermedad de Hodgkin Recurrente | Enfermedad de Hodgkin refractario | Enfermedad de Hodgkin, PediátricaEstados Unidos
-
Shanghai Zhongshan HospitalReclutamientoLinfoma | Linfoma de Hodgkin | No linfoma de HodgkinPorcelana
-
GenmabReclutamientoNo linfoma de Hodgkin | Linfoma de Hodgkin clásicoEstados Unidos, Australia
Ensayos clínicos sobre Nilotinib
-
Novartis PharmaceuticalsTerminadoHipertensión arterial pulmonarSuiza, Estados Unidos, Alemania, Singapur, Corea, república de, Canadá
-
XSpray MicroparticlesTerminado
-
Georgetown UniversityDesconocidoEnfermedad de Parkinson | Enfermedad de Parkinson con demenciaEstados Unidos
-
Niguarda HospitalTerminadoLeucemia mieloide en fase crónicaItalia
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Aún no reclutando
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... y otros colaboradoresReclutamientoLeucemia mieloide crónica, fase crónica | NilotinibPorcelana
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActivo, no reclutandoTumor tenosinovial de células gigantes | Sinovitis villonodular pigmentada | Tumor de células gigantes de tipo difusoEstados Unidos
-
Novartis PharmaceuticalsYa no está disponibleSíndrome hipereosinofílico (SHE)
-
Novartis PharmaceuticalsYa no está disponible
-
Novartis PharmaceuticalsTerminado